AR+ Triple Negative Breast Cancer Clinical Trial

Learn about a phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer. http://www.bigtencrc.org

الفئة